SCHEMBL2766450

SCHEMBL2766450

COCOc1ccc([N+](=O)[O-])cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.63
HPGD P15428 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
RAB9A P51151 2/20 0.63
NPC1 O15118 1/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
LMNA P02545 4/20 0.60
ALDH1A1 P00352 3/20 0.59
KMT2A Q03164 3/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HSD17B10 Q99714 1/20 0.51
PDE7A Q13946 1/20 0.51
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 2/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5390051 0.88 HSD17B10 (0.51) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL3441911 0.86 MAPT (0.69) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL4257395 0.85 PTGS2 (0.59) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL4257401 0.85 PTGS2 (0.59) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL6816187 0.84 MAPT (0.79) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL30235266 0.83 HTT (0.58) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL5407163 0.83 HTT (0.58) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL18087973 0.83 HTT (0.58) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL29435299 0.82 MAPT (0.67) MAPTHPGDSMN1; SMN2RAB9ANPC1
SCHEMBL512092 0.82 MAPT (0.67) MAPTHPGDSMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627871-B1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE ASKA PHARM CO LTD (JP) 2010-04-14 EP disclosed
US-7449466-B2 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-11-11 US disclosed
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
US-7030138-B2 Benzamidine derivatives SANKYO COMPANY, LIMITED (JP) 2006-04-18 US disclosed
EP-1627871-A1 CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE Teikoku Hormone Mfg. Co., Ltd. (JP) 2006-02-22 EP disclosed
US-20040147555-A1 Benzamidine derivatives SANKYO COMPANY, LIMITED (JP) 2004-07-29 US disclosed
EP-1375482-A1 BENZAMIDINE DERIVATIVE Sankyo Company, Limited (JP) 2004-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147555-A1 Benzamidine derivatives F9, F7, F2 MAPT 4885/4885HPGD 3547/4885SMN1; SMN2 4174/4885
US-20060189625-A1 Cyclic aminophenyl sulfamate derivative SHBG, STS, ARSA MAPT 4852/4885HPGD 1454/4885SMN1; SMN2 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.